Skip to main content
NCBI home page
Gut logoLink to Gut
. 1993 Oct;34(10):1458–1462. doi: 10.1136/gut.34.10.1458

Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.

C J Hawkey 1, R G Long 1, K D Bardhan 1, K G Wormsley 1, K M Cochran 1, J Christian 1, I K Moules 1
PMCID: PMC1374562  PMID: 8244121

Abstract

The purpose of this study was to compare duodenal ulcer healing, symptom relief, and safety of lansoprazole (a new proton pump inhibitor) given at doses of 30 mg and 60 mg, in the morning with ranitidine 300 mg at bedtime. Two hundred and eighty nine patients were enrolled over a 20 month period in a double blind randomised parallel group comparative study set in outpatient endoscopy units of six United Kingdom medical centres. Patients were randomised to receive lansoprazole 30 mg in the morning (n = 95), 60 mg in the morning (n = 96), or ranitidine 300 mg at bedtime (n = 98) for four weeks. Efficacy was assessed by gastroscopy at study entry and after two and four weeks of treatment. Symptom relief was monitored by patient diaries and physician review at two and four weeks. Both doses of lansoprazole resulted in significantly greater ulcer healing than ranitidine after two and four weeks. Respective healing rates on lansoprazole 30 mg, 60 mg, and ranitidine 300 mg were 78%, 80%, and 60% after two weeks and 93%, 97%, and 81% after four weeks. Patients on lansoprazole 30 mg (p = 0.002) and lansoprazole 60 mg (p = 0.026) also recorded greater relief of night time pain in the diary cards during the first seven days of treatment than those on ranitidine. Patients on lansoprazole 60 mg reported significantly better pain relief at their two week visit compared with those receiving ranitidine (p = 0.007). There were no differences between treatment groups in the occurrence or pattern of adverse drug reactions during the trial. It is concluded that for patients with duodenal ulcer, lansoprazole 30 mg or 60 mg is associated with faster ulcer healing and better symptom relief than ranitidine 300 mg at bedtime. There were no significant differences between lansoprazole 30 mg and 60 mg. These data indicate that lansoprazole should be used at a once daily dose of 30 mg for the treatment of duodenal ulcer.

Full text

PDF
1458

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barradell L. B., Faulds D., McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1992 Aug;44(2):225–250. doi: 10.2165/00003495-199244020-00007. [DOI] [PubMed] [Google Scholar]
  2. Fellenius E., Berglindh T., Sachs G., Olbe L., Elander B., Sjöstrand S. E., Wallmark B. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature. 1981 Mar 12;290(5802):159–161. doi: 10.1038/290159a0. [DOI] [PubMed] [Google Scholar]
  3. Hotz J., Kleinert R., Grymbowski T., Hennig U., Schwarz J. A. Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. Aliment Pharmacol Ther. 1992 Feb;6(1):87–95. doi: 10.1111/j.1365-2036.1992.tb00548.x. [DOI] [PubMed] [Google Scholar]
  4. Londong W., Barth H., Dammann H. G., Hengels K. J., Kleinert R., Müller P., Rohde H., Simon B. Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment Pharmacol Ther. 1991 Jun;5(3):245–254. doi: 10.1111/j.1365-2036.1991.tb00025.x. [DOI] [PubMed] [Google Scholar]
  5. Müller P., Dammann H. G., Leucht U., Simon B. Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther. 1989 Apr;3(2):193–198. doi: 10.1111/j.1365-2036.1989.tb00205.x. [DOI] [PubMed] [Google Scholar]
  6. Nagaya H., Satoh H., Kubo K., Maki Y. Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther. 1989 Feb;248(2):799–805. [PubMed] [Google Scholar]
  7. Nagaya H., Satoh H., Maki Y. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther. 1990 Mar;252(3):1289–1295. [PubMed] [Google Scholar]
  8. Satoh H., Inatomi N., Nagaya H., Inada I., Nohara A., Nakamura N., Maki Y. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther. 1989 Feb;248(2):806–815. [PubMed] [Google Scholar]
  9. Schwartz D., Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967 Aug;20(8):637–648. doi: 10.1016/0021-9681(67)90041-0. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES